HC Wainwright Forecasts Strong Price Appreciation for Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine (NASDAQ:IRON) had its price objective upped by analysts at HC Wainwright from $118.00 to $120.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 52.07% from the company’s current price.

IRON has been the subject of several other research reports. Wall Street Zen raised Disc Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a report on Friday, July 17th. Morgan Stanley increased their target price on shares of Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, June 15th. Finally, Wedbush restated an “outperform” rating and set a $88.00 price target on shares of Disc Medicine in a report on Wednesday, June 10th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $106.00.

Disc Medicine Trading Up 1.4%

IRON opened at $78.91 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. Disc Medicine has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The company’s 50 day moving average price is $73.30 and its two-hundred day moving average price is $69.69. The firm has a market capitalization of $3.01 billion, a price-to-earnings ratio of -11.99 and a beta of 1.00.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.71) by $0.17. As a group, research analysts predict that Disc Medicine will post -6.62 earnings per share for the current year.

Insiders Place Their Bets

In other Disc Medicine news, CEO John D. Quisel sold 34,000 shares of the stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $70.21, for a total transaction of $2,387,140.00. Following the transaction, the chief executive officer directly owned 226,064 shares in the company, valued at approximately $15,871,953.44. This represents a 13.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rahul Khara sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $70.22, for a total transaction of $526,650.00. Following the sale, the insider directly owned 52,173 shares of the company’s stock, valued at approximately $3,663,588.06. This trade represents a 12.57% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 105,712 shares of company stock worth $7,597,536. Corporate insiders own 3.76% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

A number of large investors have recently bought and sold shares of the stock. ANTIPODES PARTNERS Ltd acquired a new position in shares of Disc Medicine during the fourth quarter valued at about $33,000. KBC Group NV acquired a new stake in shares of Disc Medicine in the 4th quarter valued at about $80,000. Persistent Asset Partners Ltd bought a new stake in Disc Medicine in the 4th quarter valued at about $141,000. Mirae Asset Global Investments Co. Ltd. increased its position in Disc Medicine by 36.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock valued at $146,000 after buying an additional 490 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in Disc Medicine by 15,137.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company’s stock worth $161,000 after buying an additional 2,422 shares during the period. 83.70% of the stock is currently owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.